News

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

22 Dec 2025

Research and Development Update – Q4 2025

22 Dec 2025

Research and Development Update – Q4 2025

22 Dec 2025

Research and Development Update – Q4 2025

22 Dec 2025

Research and Development Update – Q4 2025

22 Dec 2025

Research and Development Update – Q4 2025

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

12 Aug 2025

SVN-SDN-14 PTSD - Positive pre-clinical results

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme

11 Jul 2025

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme

26 Jun 2025

Initiation of research coverage by Singer Capital Markets

26 Jun 2025

Initiation of research coverage by Singer Capital Markets

26 Jun 2025

Initiation of research coverage by Singer Capital Markets

26 Jun 2025

Initiation of research coverage by Singer Capital Markets

26 Jun 2025

Initiation of research coverage by Singer Capital Markets

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds

23 Jun 2025

Allowance of U.S. patent covering AI-supported CNS discovery programme compounds